TAVR with a Trilogy valve in LVAD patients with AR shows early promise

Transcatheter aortic valve replacement (TAVR) with the Trilogy Transcatheter Heart Valve (THV) from JenaValve may be both safe and effective in patients with a left ventricular assist device (LVAD) and severe aortic regurgitation (AR). That was the primary takeaway of new registry data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 meeting in San Diego and published in JACC.[1]

Back in March, the Trilogy THV became the first TAVR device to receive U.S. Food and Drug Administration (FDA) approval for the treatment of symptomatic, severe AR. Just a few months later, the U.S. Centers for Medicare and Medicaid Services (CMS) announced it may cover TAVR in patients with AR. 

This latest analysis, JENA-VAD, explored the potential of using the Trilogy THV to treat AR in patients with an LVAD. These individuals face an increased risk of recurrent heart failure, and treatment with other TAVR valves has been associated with mixed results. The hope was that using a device built specifically with AR in mind could offer hope for these high-risk patients.

Researchers tracked data from 50 patients with a mean age of 69.2 years old. Forty percent of patients were women, and the median follow-up period was 105 days.

Overall, the technical success rate and 30-day device success rate were both 96%. No death, myocardial infarctions or strokes were reported after 30 days, and no patients experienced moderate or greater prosthetic regurgitation. In addition, there were no reports of valve migration—previously known to be a problem when attempting TAVR in patients with AR—and no second valves were needed.

Subscribe to Cardiovascular Business News

TCT 2026 in San Diego

The authors also found that treatment with the Trilogy THV was associated with an improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score. The mean KCCQ was 48.8 at baseline and 64.5 after 30 days.

Another key takeaway was the identification of leaflet thickening or thrombosis in the follow-up imaging of 11 patients. These events were symptomatic for just two patients: one had a transient ischemic attack on day 116 and another required valve-in-valve implant on day 146. The authors are still working to learn more about this finding, noting that “its significance on continuous-flow support is unresolved.” 

JENA-VAD is part of the larger ALIGN-AR clinical trial. Researchers emphasized that the long-term safety and effectiveness of treating these high-risk individuals with TAVR has yet to be established. 

“Confirmation in the full 50-patient cohort with one-year follow-up, including valve durability, systematic assessment of leaflet thrombosis and effects on LVAD physiology and survival, is needed to define the role of this therapy,” wrote first author Ravi Ramana, DO, a cardiologist with Health Care Centers of Illinois and principal investigator of the JENA-VAD registry, and colleagues.

Ramana also commented on these data in a prepared statement from JenaValve.

“It remains early, but we look forward to continuing to follow these patients,” he said. “The thrombosis findings and open questions about anticoagulation in this population call for systematic imaging and longer follow-up, and the one-year results will be essential.”

Read the full study in JACC, the flagship journal of the American College of Cardiology, here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News